Welcome to our dedicated page for MBX Biosciences news (Ticker: MBX), a resource for investors and traders seeking the latest updates and insights on MBX Biosciences stock.
MBX Biosciences, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, and its news flow reflects progress across multiple clinical programs and corporate initiatives. Company press releases and investor updates highlight developments from its proprietary Precision Endocrine Peptide™ (PEP™) platform, including clinical data, trial milestones, and financing activities.
News for MBX often centers on its lead candidates canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291. Coverage includes topline and follow-up results from the Phase 2 Avail™ trial of once-weekly canvuparatide in chronic hypoparathyroidism, initiation and progress of the Phase 2a STEADI™ trial of imapextide for post-bariatric hypoglycemia, and design and enrollment updates for the Phase 1 trial of MBX 4291 as a GLP-1/GIP co-agonist prodrug for obesity. MBX also issues releases on expected data readouts, planned regulatory interactions, and preparation for Phase 3 development.
Investors following MBX news will also see announcements related to public equity offerings, cash runway disclosures, and participation in major healthcare and investor conferences such as the J.P. Morgan Healthcare Conference and various cardiometabolic and obesity-focused forums. These items provide context on how the company funds its pipeline and communicates its strategy to the market.
This news page aggregates such updates so readers can track MBX’s clinical milestones, pipeline expansion in obesity, and key regulatory and financing events in one place. For those monitoring MBX stock or the broader endocrine and metabolic drug development space, the feed offers an organized view of how the company reports its progress over time.
MBX Biosciences (Nasdaq: MBX) reported full 12-week Phase 2 Avail™ and one-year open-label extension data for once-weekly canvuparatide in chronic hypoparathyroidism.
Key results include 63% responders vs 31% placebo at 12 weeks, 57% responders at one year, sustained calcium control, improved eGFR, physiologic bone remodeling patterns, generally mild/moderate AEs, and plans to start a Phase 3 trial in Q3 2026.
MBX Biosciences (Nasdaq: MBX) will host a virtual investor webcast and conference call at 8:00 am ET on June 12, 2026 to discuss once-weekly canvuparatide presentations at ENDO 2026 in Chicago.
The event will cover Phase 2 Avail 12-week results and one-year open-label extension data.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharma company developing precision peptide therapies for endocrine and metabolic disorders, will present at the Jefferies 2026 Global Healthcare Conference in New York City.
The company’s leadership will present on June 3, 2026, with a live webcast and 90-day replay available.
MBX Biosciences (Nasdaq: MBX) reported preliminary blinded Phase 1 data for obesity candidate MBX 4291, showing mean weight loss of 7% at 8 weeks in the first MAD Part B cohort (n=8, including 2 placebo) and a pharmacokinetic profile supporting potential once-monthly dosing.
The company also nominated once-monthly amycretin prodrug MBX 5765, plans a GLP-1/GIP/GCG triple agonist candidate in Q3 2026, achieved proof of concept for imapextide in PBH, and expects 12-week MBX 4291 MAD Part C data in Q4 2026.
MBX Biosciences (Nasdaq: MBX) reported Q1 2026 results and program milestones on May 7, 2026. Key items: $440.0 million in cash and marketable securities expected to fund operations into 2029; Phase 2 canvuparatide data accepted for ENDO 2026 presentations; Phase 3 for once-weekly canvuparatide remains on track to start in Q3 2026. MBX will host Obesity Day May 11 with initial blinded MBX 4291 data; multiple obesity candidate nominations expected in 2026.
MBX Biosciences (Nasdaq: MBX) appointed Mark R. Soued as Chief Commercial Officer effective May 2026 and granted an inducement equity award.
The award, approved under Nasdaq Listing Rule 5635(c)(4), is non-qualified stock options for 160,000 shares at a $29.78 exercise price, 10-year term, vesting over four years starting April 29, 2026.
MBX Biosciences (Nasdaq: MBX) will host an in-person and virtual Obesity Day on May 11, 2026 at 10:30 a.m. ET to provide an update on its expanding obesity portfolio and Precision Endocrine Peptide™ (PEP™) platform.
Speakers include Richard DiMarchi, Ph.D., and Katherine H. Saunders, M.D., followed by a live Q&A. The live webcast is available in the Events section of the MBX Biosciences investor website and a replay will be archived for ~90 days.
MBX Biosciences (Nasdaq: MBX) announced an inducement equity award for new Chief Business Officer Karen Basbaum on April 3, 2026. The grant is for 130,000 non-qualified stock options with an exercise price of $32.29, equal to the Nasdaq closing price on April 1, 2026.
The options carry a 10-year term and vest over four years (25% on the one-year anniversary of March 9, 2026, then monthly over three years), and were approved under Nasdaq Listing Rule 5635(c)(4).
MBX Biosciences (Nasdaq: MBX) reported Q4 and full-year 2025 results and clinical progress on March 12, 2026. Key clinical milestones include an FDA End-of-Phase 2 meeting and a Phase 3 start for once-weekly canvuparatide on track for Q3 2026, plus obesity candidate nominations in Q2–Q3 2026.
Pro forma cash and investments totaled $459.1 million as of Dec 31, 2025, expected to fund operations into 2029; 2025 net loss was $87.0 million.
MBX Biosciences (Nasdaq: MBX) appointed Karen Basbaum as Chief Business Officer effective March 10, 2026. Ms. Basbaum brings 20+ years in corporate strategy and business development, including leadership on partnerships and transactions totaling over $10 billion in potential value and roles tied to significant industry M&A.
The hire is positioned to advance MBX’s precision peptide pipeline and to pursue strategic partnerships, financings, and transactions to accelerate development and commercialization of therapies for endocrine and metabolic disorders.